biotech

Shortselling and the latest trial results

For this brand new episode of Finding the Front we are so fortunate to have biotech and life sciences veteran Matt Callahan on the show.

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s biotech market.

Find out where the experts see big growth opportunities and the ways they are investing.

Extended interview with CEO Gary Phillips

This $60m ASX-listed biotech, with a cutting-edge pipeline of transformative therapies, stands at a key inflection point for value creation.

Platinum Asset Management's biotech specialist Dr Bianca Ogden outlines the major opportunities she is seeing in the sector.

The Pharma & Biotech market had a relatively positive month with 41.5% of the coverage universe posting positive share price movements for the month of September. Over...

At Livewire Live 2024, Plato Investment Management's Dr David Allen shared his top pick for the coming years.

The third panel session at Livewire Live 2024 explored the stocks the experts love to those they are avoiding.

Ten years ago, radiology software company Pro Medicus (ASX:PME) was trading at just 86 cents. Yesterday, with a share price of $149, investors have seen their money...

In this wire, we take a look at five ASX-listed pharma & biotech companies whose share prices rallied in July.

There were three companies in the Pharma & Biotech sector whose share prices rallied 70%+ in June, although share price increases for the sector were relatively muted...

With the healthcare sector in a deep and prolonged downturn, valuations of public and private R&D stage companies are very attractive.

Markets were more subdued in April after the strong start to the year. The S&P/ASX 200 Accumulation Index was down 2.9% and the S&P/ASX Small Ordinaries Accumulation...

Drug development pipelines are the lifeblood of the pharmaceutical industry. It is crucial for investors to understand milestones like FDA approvals and the impact of...

The Pharma and Biotech market was relatively buoyant in March with 49% of share prices in the coverage universe increasing for the month. There was some...

There is much more to come from Neuren. Following two years of substantial progress, we see significant upside from current levels.

Below, we take a look at four stocks that have been amongst the best performers in the first two months of the new year.

Telix Pharmaceuticals has just reported its first year of positive operating cashflow... helping it to achieve NPAT.